SKBI should be concentrating on getting their accounting spic and span.
When they talk about their accounting controls not being up to snuff, they are keeping the stock at these levels. You must be aware or all the sleezy short smear jobs on these chinese companies. Manangement needs to smarten up.
The main drop occurred when they announced a dilution - which they subsequently recanted on.
If they can run the business without needing dilution, as they have said they could, then the stock should at least maintain these previous valuations (around $8) - if the vaccine demand is as good as they say then it could start making operating cash and that would be a game changer.